+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Fabry Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Fabry Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 50 Pages
  • Global
From
Diabetic Neuropathic Pain- Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Neuropathic Pain- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Nephropathy- Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Nephropathy- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Diabetic Foot Ulcers - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Foot Ulcers - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Acute Pancreatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Acute Pancreatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Metabolic Acidosis - Pipeline Insight, 2025 - Product Thumbnail Image

Metabolic Acidosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2025 - Product Thumbnail Image

Fibroblast Growth Factor 2 (FGFR2) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Dementia With Diabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Dementia With Diabetes - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chronic Pancreatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Pancreatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2025 - Product Thumbnail Image

Hereditary Transthyretin Amyloidosis (hATTR) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Diabetes - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetes - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 450 Pages
  • Global
From
Pediatric Growth Hormone Deficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Pediatric Growth Hormone Deficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Gout - Pipeline Insight, 2025 - Product Thumbnail Image

Gout - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Adult-onset Growth Hormone Deficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Adult-onset Growth Hormone Deficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Diabetic Cardiomyopathy - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Cardiomyopathy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
SMO Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

SMO Protein Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Exportin-1 Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Exportin-1 Protein Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025 - Product Thumbnail Image

Glucagon-Like Peptide 1 Receptor Agonists - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Enhancer Of Zeste Homolog 2 Protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Enhancer Of Zeste Homolog 2 Protein Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Amyloid Beta-protein Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Amyloid Beta-protein Inhibitors - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more